183 related articles for article (PubMed ID: 15287270)
1. Outcomes research in cancer clinical trial cooperative groups: the RTOG model.
Bruner DW; Movsas B; Konski A; Roach M; Bondy M; Scarintino C; Scott C; Curran W
Qual Life Res; 2004 Aug; 13(6):1025-41. PubMed ID: 15287270
[TBL] [Abstract][Full Text] [Related]
2. The RTOG Outcomes Model: economic end points and measures.
Konski A; Watkins-Bruner D;
Expert Opin Pharmacother; 2004 Mar; 5(3):513-9. PubMed ID: 15013920
[TBL] [Abstract][Full Text] [Related]
3. Outcomes research in cancer symptom management trials: the Radiation Therapy Oncology Group (RTOG) conceptual model.
Bruner DW
J Natl Cancer Inst Monogr; 2007; (37):12-5. PubMed ID: 17951225
[TBL] [Abstract][Full Text] [Related]
4. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
[TBL] [Abstract][Full Text] [Related]
5. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
[TBL] [Abstract][Full Text] [Related]
6. The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer.
Byhardt RW
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1513-25. PubMed ID: 7635796
[TBL] [Abstract][Full Text] [Related]
7. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
Hornberger J; Hirsch FR; Li Q; Page RD
Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients.
Ramaekers BL; Joore MA; Lueza B; Bonastre J; Mauguen A; Pignon JP; Le Pechoux C; De Ruysscher DK; ; Grutters JP
J Thorac Oncol; 2013 Oct; 8(10):1295-307. PubMed ID: 24457241
[TBL] [Abstract][Full Text] [Related]
10. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience.
Machtay M; Hsu C; Komaki R; Sause WT; Swann RS; Langer CJ; Byhardt RW; Curran WJ
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):667-71. PubMed ID: 15927409
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
12. Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
Bennett CL; Smith TJ; George SL; Hillner BE; Fleishman S; Niell HB
J Clin Oncol; 1995 Sep; 13(9):2457-63. PubMed ID: 7545222
[TBL] [Abstract][Full Text] [Related]
13. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
[TBL] [Abstract][Full Text] [Related]
14. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database.
Werner-Wasik M; Paulus R; Curran WJ; Byhardt R
Clin Lung Cancer; 2011 Jul; 12(4):245-51. PubMed ID: 21726824
[TBL] [Abstract][Full Text] [Related]
15. Toxicities in RTOG combined-modality trials for inoperable non-small-cell lung cancer.
Byhardt RW
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):116-20. PubMed ID: 10550835
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA
J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Thongprasert S; Tinmanee S; Permsuwan U
Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.
Lopez PG; Stewart DJ; Newman TE; Evans WK
Cancer Prev Control; 1997; 1(1):18-27. PubMed ID: 9765723
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
